Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fate Therapeutics (FATE) Return on Capital Employed (2016 - 2025)

Fate Therapeutics' Return on Capital Employed history spans 13 years, with the latest figure at 0.5% for Q4 2025.

  • For Q4 2025, Return on Capital Employed fell 1.0% year-over-year to 0.5%; the TTM value through Dec 2025 reached 0.5%, down 1.0%, while the annual FY2025 figure was 0.43%, 5.0% up from the prior year.
  • Return on Capital Employed reached 0.5% in Q4 2025 per FATE's latest filing, up from 0.53% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.17% in Q2 2021 to a low of 0.54% in Q2 2025.
  • Average Return on Capital Employed over 5 years is 0.39%, with a median of 0.42% recorded in 2023.
  • Peak YoY movement for Return on Capital Employed: increased 21bps in 2021, then dropped -27bps in 2022.
  • A 5-year view of Return on Capital Employed shows it stood at 0.25% in 2021, then plummeted by -102bps to 0.5% in 2022, then rose by 22bps to 0.39% in 2023, then decreased by -25bps to 0.49% in 2024, then fell by -2bps to 0.5% in 2025.
  • Per Business Quant, the three most recent readings for FATE's Return on Capital Employed are 0.5% (Q4 2025), 0.53% (Q3 2025), and 0.54% (Q2 2025).